SeaStar Medical updates executive separation terms

SeaStar Medical Holding Corporation filed an amended report describing a new separation and release agreement with Mr. Green.

Rhea-AI Filing Summary

SeaStar Medical Holding Corporation filed an amended report describing a new separation and release agreement with Mr. Green. The agreement, entered into on June 10, 2026, provides a mutual resolution of issues surrounding a previously disputed not-for-cause termination.

Under this new agreement, SeaStar Medical has agreed to pay Mr. Green more than was disclosed in the earlier report signed on August 19, 2025. The filing indicates all claims related to that dispute are being released as part of the mutual resolution.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

separation and release agreement, not-for-cause termination, emerging growth company, Common Stock par value $0.0001 per share, +1 more

5 terms

separation and release agreement financial

"the Company and Mr. Green entered into a separation and release agreement releasing all claims"

not-for-cause termination financial

"surrounding the disputed not-for-cause termination referenced in the 8-K signed on August 19, 2025"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Common Stock par value $0.0001 per share financial

"Common Stock par value $0.0001 per share | | ICU | | The Nasdaq Stock Market LLC"

Warrants, each whole warrant exercisable for one share of Common Stock financial

"Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did SeaStar Medical (ICU) disclose in this 8-K/A?

SeaStar Medical disclosed a new separation and release agreement with Mr. Green. The agreement replaces prior terms related to his disputed not-for-cause termination and provides for a higher payment than was previously reported in the August 19, 2025 filing.

When did SeaStar Medical (ICU) sign the new separation agreement with Mr. Green?

SeaStar Medical and Mr. Green entered into the new separation and release agreement on June 10, 2026. The company then formally filed this amended report, signed by its Chief Executive Officer, to update investors on the revised contractual terms.

How does the new agreement affect payments to Mr. Green from SeaStar Medical (ICU)?

The company states it will pay Mr. Green more than the amount previously disclosed. While the exact figure is not included, the filing clarifies that the revised package is richer than what was described in the August 19, 2025 report.

What dispute is SeaStar Medical (ICU) resolving with Mr. Green?

The agreement resolves claims surrounding Mr. Green’s previously disputed not-for-cause termination. By signing the separation and release agreement, both parties mutually settle those issues and release related claims, according to the company’s description in the amended report.

Who signed the SeaStar Medical (ICU) amended report about Mr. Green?

The amended report was signed by Eric Schlorff, SeaStar Medical’s Chief Executive Officer. His signature indicates the company’s authorization of the updated disclosure describing the June 10, 2026 separation and release agreement with Mr. Green.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:14 PM Learn about SEC filing dates

David Green Separation Update true 0001831868 0001831868 2025-08-13 2025-08-13 0001831868 icu:CommonStockParValue00001PerShareCustomMember 2025-08-13 2025-08-13 0001831868 icu:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockFor1150PerShareCustomMember 2025-08-13 2025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

SeaStar Medical Holding Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-39927	85-3681132
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
3513 Brighton Blvd, Suite 410
Denver, Colorado		80216
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 844 427-8100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock par value $0.0001 per share		ICU		The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share		ICUCW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 10, 2026, SeaStar Medical Holding Corporation (the "Company") and Mr. Green entered into a separation and release agreement releasing all claims surrounding the disputed not-for-cause termination referenced in the 8-K signed on August 19, 2025, with a mutual resolution, pursuant to which SeaStar has agreed to pay Mr. Green more than what was previously disclosed in the 8-K signed on August 19, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SeaStar Medical Holding Corporation

		By:	/s/ Eric Schlorff
Date:	June 23, 2026	Name:	Eric Schlorff
		Title:	Chief Executive Officer

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 4.0 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 14.4 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 19.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 14.5 KB